UBS: Citi on China Healthcare — AI-Driven Drug Discovery Is the Next Big Opportunity; Top Pick Insilico Medicine

Citi argues AI-driven drug discovery (AIDD) is accelerating in China and drawing intense investor attention, anchored by AI's speed and cost advantages. Against Frost & Sullivan's estimate of US$313bn in 2026E global pharmaceutical R&D spend, AIDD penetration is only about 6%; the global AI drug-discovery ecosystem should reach roughly US$50bn by 2030E, concentrated in data generation, wet-lab validation, and AI-native discovery. Disclosed AI-enabled collaboration values exceed US$43bn, evidence AI is shifting from tool to asset creator. Near term, Citi finds AI wet-lab validation players ('shovel sellers') most attractive; longer term it prefers AI-native developers such as top pick Insilico Medicine, whose proprietary platform repeatedly produces differentiated clinical assets. Efficiency evidence: first-in-class development traditionally takes about 13 years versus about 8 with AI; AI can virtually screen billions of molecules and synthesize only hundreds in 2-3 years, versus roughly 5,000 molecules over 4-6 years; F&S estimates US$54bn, or 50%, in industry savings. Crucially, Citi stresses faster is proven while better is not—higher clinical success rates remain unvalidated end-to-end. Citi ratings: Insilico Medicine Buy/High Risk (target price HK$85); HitGen Buy/High Risk (target price RMB45); XtalPi initiated at Neutral/High Risk (target price HK$8.0).